Table 1.
Demographic data for DIRECT patients treated with EGFR TKIs
| Category | n (% of total cohort) |
|---|---|
| Median age (range), y | 62 (27–92) |
| Gender | |
| Female | 437 (42.8) |
| Male | 286 (28) |
| Unknown | 298 (29.2) |
| Ethnicity | |
| Caucasian | 189 (18.5) |
| Asian | 680 (66.6) |
| African-American | 2 (0.2) |
| Unknown | 150 (14.7) |
| Histologya | |
| Adenocarcinoma | 672 (65.8) |
| Adenosquamous | 5 (0.5) |
| Bronchioloalveolar | 23 (2.3) |
| Large cell | 15 (1.5) |
| Squamous | 34 (3.3) |
| Spindle | 1 (0.1) |
| Unknown | 96 (9.4) |
| Smoking status | |
| Current | 55 (5.4) |
| Former smokers | 215 (21.1) |
| Never smokers | 433 (42.4) |
| NSCLC nosb | 175 (17.5) |
| Unknown | 318 (31.2) |
| Stage | |
| I | 4 (0.4) |
| IB | 1 (0.1) |
| IIA | 3 (0.3) |
| IIB | 5 (0.5) |
| III | 2 (0.2) |
| IIIA | 25 (0.25) |
| IIIB | 39 (3.8) |
| IIIB/IV | 401 (39.3) |
| IV | 209 (20.5) |
| Unknown | 332 (32.5) |
| ECOG performance status | |
| 0 | 11 (1.1) |
| 1 | 35 (3.4) |
| 2 | 21 (2.1) |
| 3 | 8 (0.8) |
| 4 | 5 (0.5) |
| Unknown | 941 (92.1) |
| Number of prior therapies before starting EGFR TKI therapy | |
| 0 | 179 (17.5) |
| 1 | 49 (4.8) |
| 2 | 86 (8.4) |
| 3 | 18 (1.8) |
| 4 | 9 (0.9) |
| 6 | 2 (0.2) |
| Unknown | 678 (66.4) |
| Total number of mutation combinations by response category | |
| De novo disease control | 149 (72.0) |
| De novo disease progression | 42 (20.3) |
| Acquired resistance | 16 (7.7) |
| TOTAL unique mutation combinations | 207 (N/A) |
Abbreviation: N/A, not applicable.
a
2004 World Health Organization (WHO) Classification used.
b
NSCLC not otherwise specified.